

15103816D

HOUSE BILL NO. 1277**AMENDMENT IN THE NATURE OF A SUBSTITUTE**

(Proposed by the House Committee on Agriculture, Chesapeake and Natural Resources)

(Patron Prior to Substitute—Delegate Yost)

House Amendments in [] — February 2, 2015

A BILL to amend and reenact §§ 3.2-801 and 54.1-3401 of the Code of Virginia and to amend the Code of Virginia by adding in Title 3.2 a chapter numbered 41.1, consisting of sections numbered 3.2-4112 through 3.2-4120, relating to industrial hemp production and manufacturing.

Be it enacted by the General Assembly of Virginia:

1. That §§ 3.2-801 and 54.1-3401 of the Code of Virginia are amended and reenacted and that the Code of Virginia is amended by adding in Title 3.2 a chapter numbered 41.1, consisting of sections numbered 3.2-4112 through 3.2-4120, as follows:

§ 3.2-801. Powers and duties of Commissioner.

The Commissioner shall exercise or perform the powers and duties imposed upon him by this chapter. The Commissioner shall make surveys for noxious weeds and when the Commissioner determines that an infestation exists within the Commonwealth, he may request the Board to declare the weed to be noxious under this chapter and the Board shall proceed as specified in § 3.2-802.

The Commissioner in coordination with the Department of Game and Inland Fisheries shall develop a plan for the identification and control of noxious weeds in the surface waters and lakes of the Commonwealth.

The Commissioner may cooperate with any person or any agency of the federal government in carrying out the provisions of this chapter.

Expenses incurred on property owned or controlled by the federal government shall be reimbursed and refunded to the appropriation from which they were expended.

The Commissioner may, upon request, cooperate with federal, other state agencies, or political subdivisions in the enforcement of the narcotics laws to the extent of preventing the spread of and destroying marijuana or hemp, Cannabis species, or other plants that produce drugs that have been condemned for destruction under the narcotics laws, and the expenses incurred shall be reimbursed and shall be refunded to the appropriation from which they were expended. Such drug producing plants are hereby declared noxious and subject to all provisions of this chapter pertaining to eradication and spread subject to the above conditions.

**CHAPTER 41.1.
INDUSTRIAL HEMP.**

§ 3.2-4112. Definitions.*As used in this chapter:*

"Grower" means any person licensed pursuant to § 3.2-4115 to grow industrial hemp as part of the industrial hemp research program.

"Hemp products" means all products made from industrial hemp, including cloth, cordage, fiber, food, fuel, paint, paper, particleboard, plastics, seed, seed meal and seed oil for consumption, and seed for cultivation.

"Industrial hemp" means all parts and varieties of the plant Cannabis sativa, cultivated or possessed by a licensed grower, whether growing or not, that contain a concentration of THC that is no greater than that allowed by federal law. Industrial hemp as defined and applied in this chapter is excluded from the definition of marijuana as found in § 54.1-3401.

"Industrial hemp research program" means the research program established pursuant to § 3.2-4120.

"Seed research" means research conducted to develop or re-create better varieties of industrial hemp, particularly for the purposes of seed production.

"Tetrahydrocannabinol" or "THC" means the natural or synthetic equivalents of the substances contained in the plant, or in the resinous extractives, of the genus Cannabis, or any synthetic substances, compounds, salts, or derivatives of the plant or chemicals and their isomers with similar chemical structure and pharmacological activity.

§ 3.2-4113. Production of industrial hemp lawful.

A. It is lawful for a person licensed pursuant to § 3.2-4115 to cultivate, produce, or otherwise grow industrial hemp in the Commonwealth for the purpose of research as part of the industrial hemp research program. No person licensed pursuant to § 3.2-4115 shall be prosecuted under § 18.2-247, 18.2-248, 18.2-248.01, 18.2-248.1, 18.2-250, or 18.2-250.1 for (i) the possession or cultivation of industrial hemp plant material or seeds as part of the industrial hemp research program or (ii) the manufacture of industrial hemp products as part of the industrial hemp research program. [In any complaint, information, or indictment, and in any action or proceeding brought for the enforcement of

ENGROSSED

HB1277EH1

60 any provision of Article 1 (§ 18.2-247 et seq.) of Chapter 7 of Title 18.2 or the Drug Control Act,
61 Chapter 34 (§ 54.1-3400 et seq.) of Title 54.1, it shall not be necessary to negate any exception, excuse,
62 proviso, or exemption contained in this chapter or the Drug Control Act, and the burden of proof of any
63 such exception, excuse, proviso, or exemption shall be on the defendant.]

64 B. Nothing in this chapter shall be construed to authorize any person to violate any federal law or
65 regulation. If any part of this chapter conflicts with a provision of federal law relating to industrial
66 hemp that has been adopted in Virginia under this chapter, the federal provision shall control to the
67 extent of the conflict.

68 [C. No person shall be prosecuted under § 18.2-247, 18.2-248, 18.2-248.01, 18.2-248.1, 18.2-250, or
69 18.2-250.1 for the involuntary growth of industrial hemp through the inadvertent natural spread of seeds
70 or pollen as a result of proximity to a licensed grower.]

71 **§ 3.2-4114. Regulations.**

72 The Board may adopt regulations pursuant to this chapter as necessary to (i) license persons to
73 grow industrial hemp or (ii) administer the industrial hemp research program.

74 **§ 3.2-4115. Issuance of licenses.**

75 A. The Commissioner shall establish a program of licensure to allow a person to grow industrial
76 hemp in the Commonwealth in a controlled fashion solely and exclusively as part of the industrial hemp
77 research program. This form of licensure shall only be allowed subject to a grant of necessary
78 permissions, waivers, or other form of valid legal status by the U.S. Drug Enforcement Administration
79 or other appropriate federal agency pursuant to applicable federal laws relating to industrial hemp.

80 B. Any person seeking to grow industrial hemp as part of the industrial hemp research program
81 shall apply to the Commissioner for a license on a form provided by the Commissioner. At a minimum,
82 the application shall include:

83 1. The name and mailing address of the applicant;

84 2. The legal description and geographic data sufficient for locating the production fields to be used
85 to grow industrial hemp. A license shall authorize industrial hemp propagation only on the land areas
86 specified in the license;

87 3. A signed statement indicating whether the applicant has ever been convicted of a felony. A person
88 with a prior felony drug conviction within 10 years of applying for a license under this section shall not
89 be eligible for the license;

90 4. Written consent allowing the sheriff's office, police department, or Department of State Police, if a
91 license is ultimately issued to the applicant, to enter the premises on which the industrial hemp is grown
92 to conduct physical inspections of industrial hemp planted and grown by the applicant and to ensure
93 compliance with the requirements of this chapter. No more than two physical inspections shall be
94 conducted under this subdivision per year, unless a valid search warrant for an inspection has been
95 issued by a court of competent jurisdiction. All testing for THC levels shall be performed as provided in
96 subsection K;

97 5. Documentation of an agreement between a public institution of higher education and the applicant
98 that states that the applicant, if licensed pursuant to this section, will be a participant in the industrial
99 hemp research program managed by that public institution of higher education;

100 6. Any other information required by the Commissioner; and

101 7. The payment of a nonrefundable application fee, in an amount set by the Commissioner.

102 C. The Commissioner shall require a state and national fingerprint-based criminal history
103 background check by the Department of State Police on any person applying for licensure. The
104 Department of State Police may charge a fee, as established by the Department of State Police, to be
105 paid by the applicant for the actual cost of processing the background check. A copy of the results of
106 the background check shall be sent to the Commissioner.

107 D. All license applications shall be processed as follows:

108 1. Upon receipt of a license application, the Commissioner shall forward a copy of the application to
109 the Department of State Police, which shall initiate its review thereof;

110 2. The Department of State Police shall, within 60 days, perform the required state and national
111 criminal history background check of the applicant; approve the application, if it is determined that the
112 requirements relating to prior criminal convictions have been met; and return all applications to the
113 Commissioner together with its findings and a copy of the state and national criminal history
114 background check; and

115 3. The Commissioner shall review all license applications returned from the Department of State
116 Police. If the Commissioner determines that all requirements have been met and that a license should be
117 granted to the applicant, taking into consideration any prior convictions of the applicant, the
118 Commissioner shall approve the application for issuance of a license.

119 E. The Commissioner may approve licenses for only those selected growers whose demonstration
120 plots will, in the discretion of the Commissioner, advance the goals of the industrial hemp research
121 program to the furthest extent possible based on location, soil type, growing conditions, varieties of

industrial hemp and their suitability for particular hemp products, and other relevant factors. The location and acreage of each demonstration plot to be grown by a license holder, as well as the total number of plots to be grown by a license holder, shall be determined at the discretion of the Commissioner.

F. An industrial hemp research program grower license shall not be subject to a minimum acreage.

G. Each license shall be valid for a period of one year from the date of issuance and may be renewed in successive years. Each annual renewal shall require the payment of a license renewal fee.

H. The Commissioner shall establish the fee amounts required for license applications and license renewals allowed under this section. All application and license renewal fees collected by the Commissioner shall be deposited in the State Treasury.

I. A copy or appropriate electronic record of each license issued by the Commissioner under this section shall be forwarded immediately to the chief law-enforcement officer of each county or city where the industrial hemp is licensed to be planted, grown, and harvested.

J. All records, data, and information filed in support of a license application shall be considered proprietary and excluded from the provisions of the Virginia Freedom of Information Act (§ 2.2-3700 et seq.).

K. The Commissioner shall be responsible for monitoring the industrial hemp grown by any license holder and shall provide for random testing of the industrial hemp for compliance with THC levels and for other appropriate purposes established pursuant to § 3.2-4114 at the cost of the license holder.

§ 3.2-4116. Industrial hemp grower license conditions.

A. A person shall obtain an industrial hemp grower license pursuant to § 3.2-4115 prior to planting or growing any industrial hemp in the Commonwealth.

B. A person granted an industrial hemp grower license pursuant to § 3.2-4115 shall:

1. Maintain records that reflect compliance with this chapter and with all other state laws regulating the planting and cultivation of industrial hemp;

2. Retain all industrial hemp production records for at least three years;

3. Allow industrial hemp crops, throughout sowing, growing, and harvesting, to be inspected by and at the discretion of the Commissioner or his designee, the Department of State Police, or the chief law-enforcement officer of the locality; and

4. Maintain a current written agreement with a public institution of higher education that states that the grower is a participant in the industrial hemp research program managed by that public institution of higher education.

§ 3.2-4117. Additional industrial hemp licenses.

A. The Board may adopt regulations as necessary to license persons to grow industrial hemp in the Commonwealth for any purpose.

B. The Commissioner may establish a program of licensure, including the establishment of any fees, to allow a person to grow industrial hemp in the Commonwealth for any purpose.

C. Subsections A and B shall only be allowed subject to the authorization of industrial hemp growth and production in the United States under applicable federal laws relating to industrial hemp.

§ 3.2-4118. Forfeiture of industrial hemp grower license.

A. The Commissioner shall deny the application, or suspend or revoke the license, of any industrial hemp grower if the grower violates any provision of this chapter. The Commissioner shall provide reasonable notice of an informal fact-finding conference pursuant to § 2.2-4019 to any industrial hemp grower in connection with the denial, suspension, or revocation of the grower's license.

B. If a license is revoked as the result of an informal hearing, the decision may be appealed, and upon appeal an administrative hearing shall be conducted in accordance with the Administrative Process Act (§ 2.2-4000 et seq.). The grower may appeal a final order to the circuit court in accordance with the Administrative Process Act.

C. The Commissioner may revoke any license of any person who has pled guilty to, or been convicted of, a felony.

§ 3.2-4119. Eligibility to receive tobacco settlement funds.

Industrial hemp growers licensed under this chapter may be eligible to receive funds from the Tobacco Indemnification and Community Revitalization Fund established pursuant to § 3.2-3106.

§ 3.2-4120. Industrial hemp research program.

A. To the extent that adequate funds are available for the program, the Commissioner shall undertake research of industrial hemp production through the establishment and oversight of an industrial hemp research program to be directly managed by public institutions of higher education. This research program shall consist primarily of demonstration plots planted and cultivated in Virginia by selected growers. The growers shall be licensed pursuant to subsection A of § 3.2-4115 prior to planting any industrial hemp.

B. As part of the industrial hemp research program directly managed by public institutions of higher

183 education, the Commissioner may:

184 1. Oversee and analyze the growth of industrial hemp by licensed growers, for agronomy research
185 and analysis of required soils, growing conditions, and harvest methods relating to the production of
186 various varieties of industrial hemp that may be suitable for various commercial hemp products;

187 2. Conduct seed research on various types of industrial hemp that are best suited to be grown in
188 Virginia, including seed availability, creation of Virginia hybrid types, and in-the-ground variety trials
189 and seed production, and may establish a program to recognize certain industrial hemp seeds as being
190 Virginia varieties of hemp seed;

191 3. Study the economic feasibility of developing an industrial hemp market in various types of
192 industrial hemp that can be grown in the Commonwealth;

193 4. Report on the estimated value-added benefits, including environmental benefits, to Virginia
194 businesses of an industrial hemp market of Virginia-grown industrial hemp varieties;

195 5. Study the agronomy research being conducted worldwide relating to industrial hemp varieties,
196 production, and use;

197 6. Research and promote on the world market industrial hemp and hemp seed that can be grown on
198 farms in the Commonwealth;

199 7. Promote research into the development of industrial hemp and commercial markets for Virginia
200 industrial hemp and hemp products;

201 8. Study the feasibility of attracting federal or private funding for the Virginia industrial hemp
202 research program; and

203 9. Study the use of industrial hemp in new energy technologies, including electricity generation,
204 biofuels, or other forms of energy resources; the growth of industrial hemp on reclaimed mine sites; the
205 use of hemp seed oil in the production of fuels; and the production costs, environmental issues, and
206 costs and benefits involved with the use of industrial hemp for energy.

207 C. The research activities outlined in subsection B shall not:

208 1. Subject the industrial hemp research program to any criminal liability under the controlled
209 substances laws of the Commonwealth. This exemption from criminal liability is a limited exemption that
210 shall be strictly construed and that shall not apply to any activities of the industrial hemp research
211 program that are not authorized; or

212 2. Alter, amend, or repeal by implication any provision of this Code relating to controlled
213 substances.

214 D. The Commissioner shall pursue any permits or waivers from the U.S. Drug Enforcement
215 Administration or appropriate federal agency that are necessary for the advancement of the industrial
216 hemp research program.

217 E. The Commissioner shall notify the Superintendent of State Police and all local law-enforcement
218 agencies of the duration, size, and location of all industrial hemp demonstration plots.

219 F. The Commissioner is permitted to cooperatively seek funds from public and private sources to
220 implement the industrial hemp research program.

221 G. By November 1, 2015, and annually thereafter, the Commissioner shall report on the status and
222 progress of the industrial hemp research program to the Governor and to the General Assembly.

223 **§ 54.1-3401. Definitions.**

224 As used in this chapter, unless the context requires a different meaning:

225 "Administer" means the direct application of a controlled substance, whether by injection, inhalation,
226 ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his
227 authorized agent and under his direction or (ii) the patient or research subject at the direction and in the
228 presence of the practitioner.

229 "Advertisement" means all representations disseminated in any manner or by any means, other than
230 by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the
231 purchase of drugs or devices.

232 "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer,
233 distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or
234 employee of the carrier or warehouseman.

235 "Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related
236 to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

237 "Animal" means any nonhuman animate being endowed with the power of voluntary action.

238 "Automated drug dispensing system" means a mechanical or electronic system that performs
239 operations or activities, other than compounding or administration, relating to pharmacy services,
240 including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of
241 all transaction information, to provide security and accountability for such drugs.

242 "Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood
243 component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or
244 analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic

arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

"Biosimilar" means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in clinically inactive compounds, such that there are no clinically meaningful differences between the reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency of the product.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the voting stock of which is actively traded on any securities exchange or in any over-the-counter market; (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a corporation's charter.

"Compounding" means the combining of two or more ingredients to fabricate such ingredients into a single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in expectation of receiving a valid prescription based on observed historical patterns of prescribing and dispensing; (ii) by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a manufacturer's product drugs for the purpose of administration to a patient, when performed by a practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person supervised by such practitioner pursuant to subdivision A 6 or A 19 of § 54.1-2901, or a person supervised by such practitioner or a licensed nurse practitioner or physician assistant pursuant to subdivision A 4 of § 54.1-2901 shall not be considered compounding.

"Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms are defined or used in Title 3.2 or Title 4.1.

"DEA" means the Drug Enforcement Administration, U.S. Department of Justice, or its successor agency.

"Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by this chapter, whether or not there exists an agency relationship.

"Device" means instruments, apparatus, and contrivances, including their components, parts, and accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals or to affect the structure or any function of the body of man or animals.

"Dialysis care technician" or "dialysis patient care technician" means an individual who is certified by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (§ 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner, physician assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a Medicare-certified renal dialysis facility.

"Dialysis solution" means either the commercially available, unopened, sterile solutions whose purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal dialysis, or commercially available solutions whose purpose is to be used in the performance of hemodialysis not to include any solutions administered to the patient intravenously.

"Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery. However, dispensing shall not include the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites operated by such practitioner or that practitioner's medical practice for the purpose of administration of such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For

306 practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a
307 practitioner to patients to take with them away from the practitioner's place of practice.

308 "Dispenser" means a practitioner who dispenses.

309 "Distribute" means to deliver other than by administering or dispensing a controlled substance.

310 "Distributor" means a person who distributes.

311 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia
312 National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to
313 any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or
314 prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect
315 the structure or any function of the body of man or animals; (iv) articles or substances intended for use
316 as a component of any article specified in clause (i), (ii), or (iii); or (v) a biological product. "Drug"
317 does not include devices or their components, parts, or accessories.

318 "Drug product" means a specific drug in dosage form from a known source of manufacture, whether
319 by brand or therapeutically equivalent drug product name.

320 "Electronic transmission prescription" means any prescription, other than an oral or written
321 prescription or a prescription transmitted by facsimile machine, that is electronically transmitted directly
322 to a pharmacy without interception or intervention from a third party from a practitioner authorized to
323 prescribe or from one pharmacy to another pharmacy.

324 "Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an
325 electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy
326 form.

327 "FDA" means the U.S. Food and Drug Administration.

328 "Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any
329 such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

330 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by
331 regulation designates as being the principal compound commonly used or produced primarily for use,
332 and which is an immediate chemical intermediary used or likely to be used in the manufacture of a
333 controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

334 "Interchangeable" means a biosimilar that meets safety standards for determining interchangeability
335 pursuant to 42 U.S.C. § 262(k)(4).

336 "Label" means a display of written, printed, or graphic matter upon the immediate container of any
337 article. A requirement made by or under authority of this chapter that any word, statement, or other
338 information appear on the label shall not be considered to be complied with unless such word,
339 statement, or other information also appears on the outside container or wrapper, if any, of the retail
340 package of such article or is easily legible through the outside container or wrapper.

341 "Labeling" means all labels and other written, printed, or graphic matter on an article or any of its
342 containers or wrappers, or accompanying such article.

343 "Manufacture" means the production, preparation, propagation, conversion, or processing of any item
344 regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or
345 independently by means of chemical synthesis, or by a combination of extraction and chemical
346 synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its
347 container. This term does not include compounding.

348 "Manufacturer" means every person who manufactures.

349 "Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds, or
350 its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its
351 seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids
352 unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana
353 include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the
354 seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the
355 genus *Cannabis*. *Marijuana shall not include industrial hemp as defined in § 3.2-4112 that is possessed,*
356 *cultivated, or manufactured by a grower licensed pursuant to § 3.2-4115.*

357 "Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to
358 the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and
359 needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with
360 no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for
361 peritoneal dialysis, and sterile water or saline for irrigation.

362 "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction
363 from substances of vegetable origin, or independently by means of chemical synthesis, or by a
364 combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative,
365 or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof
366 which is chemically equivalent or identical with any of the substances referred to in clause (i), but not
367 including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and

any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain cocaine or ecgonine.

"New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling, except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

"Nuclear medicine technologist" means an individual who holds a current certification with the American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification Board.

"Official compendium" means the official United States Pharmacopoeia National Formulary, official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

"Official written order" means an order written on a form provided for that purpose by the U.S. Drug Enforcement Administration, under any laws of the United States making provision therefor, if such order forms are authorized and required by federal law, and if no such order form is provided then on an official form provided for that purpose by the Board of Pharmacy.

"Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under Article 4 (§ 54.1-3437 et seq.), the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

"Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

"Original package" means the unbroken container or wrapping in which any drug or medicine is enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor for use in the delivery or display of such article.

"Person" means both the plural and singular, as the case demands, and includes an individual, partnership, corporation, association, governmental agency, trust, or other institution or entity.

"Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in a manner complying with the laws and regulations for the practice of pharmacy and the sale and dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy and the pharmacy's personnel as required by § 54.1-3432.

"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

"Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01, licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator, or other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe and administer, or conduct research with respect to a controlled substance in the course of professional practice or research in the Commonwealth.

"Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription.

"Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such drugs or medical supplies.

"Prescription drug" means any drug required by federal law or regulation to be dispensed only pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353(b)).

"Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a controlled substance or marijuana.

"Proprietary medicine" means a completely compounded nonprescription drug in its unbroken, original package which does not contain any controlled substance or marijuana as defined in this chapter

429 and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general
430 public by or under the authority of the manufacturer or primary distributor, under a trademark, trade
431 name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of
432 this chapter and applicable federal law. However, this definition shall not include a drug that is only
433 advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic,
434 a drug that may be dispensed only upon prescription or the label of which bears substantially the
435 statement "Warning - may be habit-forming," or a drug intended for injection.

436 "Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei
437 with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or
438 radionuclide generator that is intended to be used in the preparation of any such substance, but does not
439 include drugs such as carbon-containing compounds or potassium-containing salts that include trace
440 quantities of naturally occurring radionuclides. The term also includes any biological product that is
441 labeled with a radionuclide or intended solely to be labeled with a radionuclide.

442 "Reference biological product" means the single biological product licensed pursuant to 42 U.S.C.
443 § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food
444 and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to
445 42 U.S.C. § 262(k).

446 "Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any
447 person, whether as an individual, proprietor, agent, servant, or employee.

448 "Therapeutically equivalent drug products" means drug products that contain the same active
449 ingredients and are identical in strength or concentration, dosage form, and route of administration and
450 that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration
451 pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent
452 edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as
453 the "Orange Book."

454 "USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

455 "Warehouser" means any person, other than a wholesale distributor, engaged in the business of
456 selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user
457 or consumer. No person shall be subject to any state or local tax by reason of this definition.

458 "Wholesale distribution" means distribution of prescription drugs to persons other than consumers or
459 patients, subject to the exceptions set forth in § 54.1-3401.1.

460 "Wholesale distributor" means any person engaged in wholesale distribution of prescription drugs
461 including, but not limited to, manufacturers; repackers; own-label distributors; private-label distributors;
462 jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses, chain drug
463 warehouses conducting wholesale distributions, and wholesale drug warehouses; independent wholesale
464 drug traders; and retail pharmacies conducting wholesale distributions. No person shall be subject to any
465 state or local tax as a wholesale merchant by reason of this definition.

466 The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter
467 shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses
468 or lenses for the eyes.

469 The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be
470 defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.